康方生物新一代HER3 ADC药物AK138d1联合依沃西单抗:首例患者入组Ib/II期乳腺癌研究,推进"IO2.0 + ADC2.0"战略

美股速递
Jun 15

康方生物的新一代HER3靶向抗体偶联药物AK138d1,与依沃西单抗联合疗法的Ib/II期乳腺癌临床研究,已迎来首例患者入组。这一进展标志着公司"免疫治疗2.0(IO2.0)与抗体偶联药物2.0(ADC2.0)"双平台协同发展战略的实质性推进。该研究旨在评估这一创新联合疗法在HER3表达阳性晚期实体瘤,特别是乳腺癌患者中的安全性、耐受性及初步疗效。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10